Proportion of cancer biomarker testing done with NGS expected to double in 2022 compared to 2019

Article tags Centralised Diagnostics (CEDx)In-vitro diagnosticsMolecular Diagnostics (MDx)Point-of-care testing (POCT)Tissue Diagnostics (TDx)EuropeIVD GatewayLabPRO PlusMolecular Diagnostics (MDx)Next Generation Sequencing (NGS)Tissue Diagnostics (TDx)

Across Europe, there are varying levels of laboratory infrastructure capacity supporting NGS testing and integration of NGS testing in cancer care.

NGS is most-commonly found in molecular and pathology laboratories, with 69% of all NGS installations in EU5 being found in molecular laboratories. However, we also expect increasing applications in hematology, virology and microbiology laboratories. 

To meet the demand for more rapid and highly sensitive cancer biomarker testing, many laboratories are using NGS. In our study in 2018/19, 8.8% of the total annual testing volume covering 14 biomarkers in EU5 was done with NGS.

Results for 2021/22 are expected to be around one and a half to two-times more. 42% of annual molecular testing volume covering 14 biomarkers at EU5 laboratories in our 2018/2019 study was done with NGS, with that proportion expected to rise in the 2021/2022 study. 

For more on the NGS cancer biomarker testing trends, download the white paper on Next-generation sequencing (NGS) in cancer biomarker testing: Testing trends in European molecular and pathology laboratories

Mon, 20th Jun 2022 Article tags Centralised Diagnostics (CEDx)In-vitro diagnosticsMolecular Diagnostics (MDx)Point-of-care testing (POCT)Tissue Diagnostics (TDx)EuropeIVD GatewayLabPRO PlusMolecular Diagnostics (MDx)Next Generation Sequencing (NGS)Tissue Diagnostics (TDx)